{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:25:17Z","timestamp":1787239517800,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["2021325"],"award-info":[{"award-number":["2021325"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070740"],"award-info":[{"award-number":["82070740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870492"],"award-info":[{"award-number":["81870492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.diabres.2025.112413","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T06:35:48Z","timestamp":1754721348000},"page":"112413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs\/ARBs use in the treatment of patients with diabetic kidney disease"],"prefix":"10.1016","volume":"227","author":[{"given":"Xu","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.diabres.2025.112413_b0005","article-title":"The Burden of Diabetes-Related Chronic Kidney Disease in China From 1990 to 2019","volume":"15","author":"Pan","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"8","key":"10.1016\/j.diabres.2025.112413_b0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2215\/CJN.0000000000000205","article-title":"Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis","volume":"18","author":"Luo","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"10.1016\/j.diabres.2025.112413_b0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"10.1016\/j.diabres.2025.112413_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.1540","article-title":"Association of Diabetic Retinopathy and Diabetic Kidney Disease With All-Cause and Cardiovascular Mortality in a Multiethnic Asian Population","volume":"2","author":"Sabanayagam","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0025","article-title":"Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension."},{"issue":"3","key":"10.1016\/j.diabres.2025.112413_b0035","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical Management of Hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.diabres.2025.112413_b0040","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"8","key":"10.1016\/j.diabres.2025.112413_b0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.diabres.2025.112413_b0050","doi-asserted-by":"crossref","unstructured":"Hoy SM. Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia [published correction appears in Drugs. 2019 Apr;79(5):591. doi: 10.1007\/s40265-019-01097-x].Drugs. 2018;78(15):1605-1613. doi:10.1007\/s40265-018-0991-6.","DOI":"10.1007\/s40265-018-0991-6"},{"issue":"9","key":"10.1016\/j.diabres.2025.112413_b0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.diabres.2025.112413_b0060","article-title":"Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study)","volume":"15","author":"Shen","year":"2024","journal-title":"Front Pharmacol."},{"issue":"4","key":"10.1016\/j.diabres.2025.112413_b0065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2019.04.032","article-title":"International Network of Chronic Kidney Disease cohort studies (iNET-CKD). Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease","volume":"96","author":"Alencar de Pinho","year":"2019","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3892\/etm.2013.1341","article-title":"Prognosis of patients with heart failure and reduced ejection fraction in China","volume":"6","author":"Xu","year":"2013","journal-title":"Exp Ther Med."},{"issue":"1","key":"10.1016\/j.diabres.2025.112413_b0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"10.1016\/j.diabres.2025.112413_b0080","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10557-020-07134-2","article-title":"Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"10.1016\/j.diabres.2025.112413_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14656566.2020.1810234","article-title":"An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia","volume":"22","author":"Takkar","year":"2021","journal-title":"Expert Opin Pharmacother."},{"issue":"2","key":"10.1016\/j.diabres.2025.112413_b0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.24920\/004327","article-title":"A Chinese Multi-Specialty Delphi Consensus to Optimize RAASi Usage and Hyperkalaemia Management in Patients with Chronic Kidney Disease and Heart Failure","volume":"39","author":"Zhao","year":"2024","journal-title":"Chin Med Sci J."},{"key":"10.1016\/j.diabres.2025.112413_b0095","doi-asserted-by":"crossref","unstructured":"Burton JO, Coats AJS, Kovesdy CP, et al. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum [published correction appears in Eur J Heart Fail. 2023 Mar;25(3):444. doi: 10.1002\/ejhf.2790].Eur J Heart Fail. 2022;24(9):1467-1477. doi:10.1002\/ejhf.2612.","DOI":"10.1002\/ejhf.2612"},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/nep.14281","article-title":"Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective","volume":"29","author":"Yap","year":"2024","journal-title":"Nephrology (Carlton)."},{"key":"10.1016\/j.diabres.2025.112413_b0105","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093\/eurheartj\/ehab670].Eur Heart J. 2021;42(36):3599-3726. doi:10.1093\/eurheartj\/ehab368.","DOI":"10.1093\/eurheartj\/ehab368"},{"issue":"18","key":"10.1016\/j.diabres.2025.112413_b0110","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.diabres.2025.112413_b0115","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2024 Jan 1;45(1):53. doi: 10.1093\/eurheartj\/ehad613].Eur Heart J. 2023;44(37):3627-3639. doi:10.1093\/eurheartj\/ehad195.","DOI":"10.1093\/eurheartj\/ehad195"},{"issue":"11 Suppl","key":"10.1016\/j.diabres.2025.112413_b0120","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.diabres.2025.112413_b0125","doi-asserted-by":"crossref","unstructured":"Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18. Published 2023 Jan 19. doi:10.1186\/s12882-022-03054-5.","DOI":"10.1186\/s12882-022-03054-5"},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0135","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","article-title":"Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study","volume":"40","author":"Agiro","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.diabres.2025.112413_b0140","article-title":"Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study","volume":"17(5):sfae083","author":"Rastogi","year":"2024","journal-title":"Clin Kidney J."},{"issue":"10","key":"10.1016\/j.diabres.2025.112413_b0145","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail."},{"issue":"9\u201310","key":"10.1016\/j.diabres.2025.112413_b0150","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000533753","article-title":"Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN","volume":"54","author":"Chinnadurai","year":"2023","journal-title":"Am J Nephrol."},{"issue":"2","key":"10.1016\/j.diabres.2025.112413_b0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.diabres.2025.112413_b0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ndt\/gfu411","article-title":"Diabetic nephropathy: landmark clinical trials and tribulations","volume":"31","author":"Chan","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.diabres.2025.112413_b0165","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lokelma-epar-public-assessment-report_en.pdf."},{"issue":"12","key":"10.1016\/j.diabres.2025.112413_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One."},{"issue":"2","key":"10.1016\/j.diabres.2025.112413_b0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10157-020-01972-y","article-title":"A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia","volume":"25","author":"Kashihara","year":"2021","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.diabres.2025.112413_b0180","doi-asserted-by":"crossref","unstructured":"Noel JA, Bota SE, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age [published correction appears in JAMA Intern Med. 2020 Apr 1;180(4):618. doi: 10.1001\/jamainternmed.2020.0159].JAMA Intern Med. 2019;179(8):1025-1033. doi:10.1001\/jamainternmed.2019.0631.","DOI":"10.1001\/jamainternmed.2019.0631"},{"issue":"5","key":"10.1016\/j.diabres.2025.112413_b0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","article-title":"Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol","volume":"102","author":"McGowan","year":"2009","journal-title":"South Med J."},{"issue":"3","key":"10.1016\/j.diabres.2025.112413_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med."},{"issue":"6","key":"10.1016\/j.diabres.2025.112413_b0195","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3393\/ac.2021.03.19","article-title":"Calcium polystyrene sulfonate associated colonic mucosal injury-innocent bystander or pathogenic culprit?: a case report and literature review","volume":"38","author":"Piwchan","year":"2022","journal-title":"Ann Coloproctol."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:02:53Z","timestamp":1772805773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"alternative-id":["S0168822725004279"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112413","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs\/ARBs use in the treatment of patients with diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112413"}}